{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:24:34Z","timestamp":1772252674420,"version":"3.50.1"},"reference-count":86,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2015,8,11]],"date-time":"2015-08-11T00:00:00Z","timestamp":1439251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Uveitis is an inflammatory process that initially starts in the uvea, but can also affect other adjacent eye structures, and is currently the fourth cause of blindness in developed countries. Corticoids are probably the most widespread treatment, but resorting to other immunosuppressive treatments is a frequent practice. Since the implication of different cytokines in uveitis has been well demonstrated, the majority of recent treatments for this disease include inhibitors or antibodies against these. Nevertheless, adequate treatment for each uveitis type entails a difficult therapeutic decision as no clear recommendations are found in the literature, despite the few protocolized clinical assays and many case-control studies done. This review aims to present, in order, the mechanisms and main indications of the most modern immunosuppressive drugs against cytokines.<\/jats:p>","DOI":"10.3390\/ijms160818778","type":"journal-article","created":{"date-parts":[[2015,8,11]],"date-time":"2015-08-11T10:38:57Z","timestamp":1439289537000},"page":"18778-18795","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["New Immunosuppressive Therapies in Uveitis Treatment"],"prefix":"10.3390","volume":"16","author":[{"given":"Salvador","family":"M\u00e9rida","sequence":"first","affiliation":[{"name":"Instituto de Ciencias Biom\u00e9dicas, Universidad CEU Cardenal Herrera, Valencia 46113, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Palacios","sequence":"additional","affiliation":[{"name":"Oftalmolog\u00eda M\u00e9dica, Fundaci\u00f3n para el Fomento de la Investigaci\u00f3n Sanitaria y Biom\u00e9dica de la Comunitat Valenciana, Valencia 46020, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amparo","family":"Navea","sequence":"additional","affiliation":[{"name":"Instituto de Ciencias Biom\u00e9dicas, Universidad CEU Cardenal Herrera, Valencia 46113, Spain"},{"name":"Oftalmolog\u00eda M\u00e9dica, Fundaci\u00f3n para el Fomento de la Investigaci\u00f3n Sanitaria y Biom\u00e9dica de la Comunitat Valenciana, Valencia 46020, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Bosch-Morell","sequence":"additional","affiliation":[{"name":"Instituto de Ciencias Biom\u00e9dicas, Universidad CEU Cardenal Herrera, Valencia 46113, Spain"},{"name":"Oftalmolog\u00eda M\u00e9dica, Fundaci\u00f3n para el Fomento de la Investigaci\u00f3n Sanitaria y Biom\u00e9dica de la Comunitat Valenciana, Valencia 46020, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2015,8,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/S0140-6736(73)91090-8","article-title":"Acute anterior uveittis and HL-A 27","volume":"2","author":"Brewerton","year":"1973","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.2147\/OPTH.S53518","article-title":"The association of human leukocyte antigen B27 with anterior uveitis in patients from the western region of Saudi Arabia: A retrospective study","volume":"7","author":"Bawazeer","year":"2013","journal-title":"Clin. Ophthalmol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Grajewski, R.S., Caramoy, A., Frank, K.F., Rubbert-Roth, A., F\u00e4tkenheuer, G., Kirchhof, B., Cursiefen, C., and Heindl, L.M. (2015). Spectrum of uveitis in a german tertiary center: Review of 474 consecutive patients. Ocul. Immunol. Inflamm.","DOI":"10.3109\/09273948.2014.1002567"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/sj.eye.6702111","article-title":"Pattern of uveitis in a referral centre in Tunisia, North Africa","volume":"21","author":"Khairallah","year":"2007","journal-title":"Eye"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"705","DOI":"10.5301\/ejo.5000278","article-title":"Review on the worldwide epidemiology of uveitis","volume":"23","author":"Miserocchi","year":"2013","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/02713680500263606","article-title":"Clinical patterns and characteristics of uveitis in a tertiary center for uveitis in China","volume":"30","author":"Yang","year":"2005","journal-title":"Curr. Eye Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/j.ophtha.2009.05.002","article-title":"Epidemiology and course of disease in childhood uveitis","volume":"116","author":"Smith","year":"2009","journal-title":"Ophthalmology"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Lloren\u00e7, V., Mesquida, M., Sainz de la Maza, M., Keller, J., Molins, B., Espinosa, G., Hernandez, M.V., Gonzalez-Mart\u00edn, J., and Ad\u00e1n, A. (2015). Epidemiology of uveitis in a western urban multiethnic population. The challenge of globalization. Acta Ophthalmol.","DOI":"10.1111\/aos.12675"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/bjo.80.9.844","article-title":"The possible impact of uveitis in blindness: A literature survey","volume":"80","author":"Rothova","year":"1996","journal-title":"Br. J. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1076\/ocii.10.4.263.15592","article-title":"Uveitis: A global perspective","volume":"10","author":"Chang","year":"2002","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.autrev.2014.05.003","article-title":"Immunotherapeutic strategies in autoimmune uveitis","volume":"13","author":"Papotto","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_12","first-page":"671417","article-title":"Macrophages and uveitis in experimental animal models","volume":"501","author":"Palacios","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00281-014-0433-9","article-title":"Autoimmune and autoinflammatory mechanisms in uveitis","volume":"36","author":"Lee","year":"2014","journal-title":"Semin. Immunopathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1167\/iovs.05-0836","article-title":"Cytokine profile in aqueous humor and sera of patients with infectious or noninfectious uveitis","volume":"47","author":"Takase","year":"2006","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/ni1254","article-title":"Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ni1261","article-title":"A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17","volume":"6","author":"Park","year":"2005","journal-title":"Nat. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3121\/cmr.4.4.294","article-title":"Cytokines and chemokines in uveitis: Is there a correlation with clinical phenotype?","volume":"4","author":"Ooi","year":"2006","journal-title":"Clin. Med. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nm1585","article-title":"TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27\/STAT1","volume":"13","author":"Yu","year":"2007","journal-title":"Nat. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3109\/10715762.2013.805882","article-title":"Lipoic acid lessens Th1-mediated inflammation in lipopolysaccharide-induced uveitis reducing selectively Th1 lymphocytes-related cytokines release","volume":"47","author":"Muriach","year":"2013","journal-title":"Free Radic. Res."},{"key":"ref_20","unstructured":"Vitale, A.T., Shulman, J.P., and Foster, C.S. (2013). Diagnosis and Treatment of Uveitis, Jaypee Brothers Medical. [2nd ed.]."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1210\/en.2012-2045","article-title":"New insights into the anti-inflammatory mechanisms of glucocorticoids: An emerging role for glucocorticoid-receptor-mediated transactivation","volume":"154","author":"Vandevyver","year":"2013","journal-title":"Endocrinology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1136\/bjo.63.11.762","article-title":"Double-blind clinical trial of topical steroids in anterior uveitis","volume":"63","author":"Dunne","year":"1979","journal-title":"Br. J. Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s004170050235","article-title":"Posterior sub-Tenon\u2019s steroid injections for the treatment of posterior ocular inflammation: Indications, efficacy and side effects","volume":"237","author":"Dafflon","year":"1999","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ajo.2008.09.011","article-title":"Comparison between intravitreal and orbital floor triamcinolone acetonide after phacoemulsification in patients with endogenous uveitis","volume":"147","author":"Roesel","year":"2009","journal-title":"Am. J. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archophthalmol.2010.339","article-title":"HURON Stufy Group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis","volume":"129","author":"Lowder","year":"2011","journal-title":"Arch. Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0002-9394(14)76692-9","article-title":"Randomized double masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis","volume":"112","author":"Nussenblatt","year":"1991","journal-title":"Am. J. Ophthalmol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.eye.6700163","article-title":"Corticosteroid-induced osteoporosis in patients with uveitis","volume":"16","author":"Jones","year":"2002","journal-title":"Eye"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/acr.20295","article-title":"American College of Rheumatology 2010 recommendations for the prevention and treatment of glucorticoid-induced osteoporosis","volume":"62","author":"Grossman","year":"2010","journal-title":"Arthritis Care Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jaut.2013.06.009","article-title":"Differential targeting of IL-2 and T cell receptor signaling pathways selectively expands regulatory T cells while inhibiting conventional T cells","volume":"44","author":"Satake","year":"2013","journal-title":"J. Autoimmun."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Ruppert, S.M., Falk, B.A., Long, S.A., and Bollyky, P.L. (2015). Regulatory T Cells Resist Cyclosporine-Induced Cell Death via CD44-Mediated Signaling Pathways. Int. J. Cell Biol., 1\u201310. 614297.","DOI":"10.1155\/2015\/614297"},{"key":"ref_31","unstructured":"Foster, C.S., Vitale, A.T., and Kump, L. (2013). Diagnosis and Treatment of Uveitis, Jaypee Brothers Medical. [2nd ed.]."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2009.08.010","article-title":"Cyclosporine for ocular inflammatory diseases","volume":"117","author":"Kempen","year":"2010","journal-title":"Ophthalmology."},{"key":"ref_33","first-page":"279","article-title":"Methotrexate in the therapy of cyclitis","volume":"69","author":"Wong","year":"1965","journal-title":"Trans. Am. Acad. Ophthalmol. Otolaryngol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1097\/IAE.0b013e318285cdbe","article-title":"Intravitreal methotrexate in the management of presumed tuberculous serpiginous-like choroiditis","volume":"33","author":"Julian","year":"2013","journal-title":"Retina"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ophtha.2009.04.020","article-title":"systemic immunosuppressive therapy for eye diseases cohort study. Methotrexate for ocular inflammatory diseases","volume":"116","author":"Gangaputra","year":"2009","journal-title":"Ophthalmology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ajo.2009.09.026","article-title":"Mycophenolate mofetil for ocular inflammation","volume":"149","author":"Daniel","year":"2010","journal-title":"Am. J. Ophthalmol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1517\/14712598.2012.688021","article-title":"The role of biologic agents in the management of non-infectious uveitis","volume":"12","author":"Heo","year":"2012","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000055677","article-title":"Aqueous humor and serum tumor necrosis factor-\u03b1 in clinical uveitis","volume":"33","author":"Santos","year":"2000","journal-title":"Ophthalmic Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1084\/jem.174.6.1483","article-title":"A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity","volume":"174","author":"Peppel","year":"1991","journal-title":"J. Exp. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/bjo.87.7.925","article-title":"Does etanercept induce uveitis?","volume":"87","author":"Reddy","year":"2003","journal-title":"Br. J. Ophthalmol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1002\/art.22918","article-title":"Do tumor necrosis factor inhibitors cause uveitis? A registry-based study","volume":"56","author":"Lim","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","article-title":"Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Beh\u00e7et disease","volume":"140","author":"Sfikakis","year":"2004","journal-title":"Ann. Intern. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1089\/jop.2006.0148","article-title":"High-dose infliximab prophylaxis in endotoxin-induced uveitis","volume":"23","author":"Salom","year":"2007","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1097\/ICO.0b013e31826a80ea","article-title":"Effectiveness of topical infliximab in a mouse model of experimental dry eye","volume":"31","author":"Li","year":"2012","journal-title":"Cornea"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1167\/iovs.12-10782","article-title":"Safety and efficacy of topical infliximab in a mouse model of ocular surface scarring","volume":"54","author":"Ferrari","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ophtha.2013.07.019","article-title":"Infliximab for the treatment of refractory noninfectious uveitis: A study of 88 patients with long-term follow-up","volume":"121","author":"Kruh","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_47","first-page":"67","article-title":"Update on the use of systemic biologic agents in the treatment of noninfectious uveitis","volume":"15","author":"Pasadhika","year":"2014","journal-title":"Biologics"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/jop.2007.0104","article-title":"Adalimumab therapy for refractory uveitis: A pilot study","volume":"24","author":"Salom","year":"2008","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jpeds.2006.04.058","article-title":"Adalimumab therapy for childhood uveitis","volume":"149","author":"Flynn","year":"2006","journal-title":"J. Pediatr."},{"key":"ref_50","first-page":"339","article-title":"Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis","volume":"47","author":"Kotaniemi","year":"2008","journal-title":"Rheumatology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.ophtha.2012.02.018","article-title":"Treatment of refractory uveitis with adalimumab: A prospective multicenter study of 131 patients","volume":"119","author":"Salom","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/eye.2011.320","article-title":"Adalimumab specifically induces CD3+; CD4+; CD25high Foxp3+; CD127\u2212 T-regulatory cells and decreases vascular endothelial growth factor plasma levels in refractory immuno-mediated uveitis: A non-randomized pilot intervention study","volume":"26","author":"Calleja","year":"2012","journal-title":"Eye"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4161\/mabs.12304","article-title":"Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor \u03b1","volume":"2","author":"Shealy","year":"2010","journal-title":"MAbs"},{"key":"ref_54","first-page":"e3","article-title":"Golimumab for uveitis","volume":"118","author":"Salom","year":"2011","journal-title":"Ophthalmology"},{"key":"ref_55","first-page":"320","article-title":"Golimumab treatment for complicated uveitis","volume":"31","author":"Miserocchi","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12348-012-0081-y","article-title":"Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis","volume":"2","author":"William","year":"2012","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/ceo.12207","article-title":"Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: Retrospective case series","volume":"42","author":"Faez","year":"2014","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/09273948.2012.741744","article-title":"Beh\u00e7et disease-associated uveitis successfully treated with golimumab","volume":"21","author":"Mesquida","year":"2013","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_59","first-page":"1534","article-title":"Ocular inflammation stimulated by intravitreal interleukin-8 and interleukin-1","volume":"32","author":"Ferrick","year":"1991","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_60","first-page":"25","article-title":"Ultrastructural analysis of interleukin-1 \u03b2-induced leukocyte recruitment to the rat retina","volume":"38","author":"Bamforth","year":"1997","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.intimp.2014.06.041","article-title":"Interleukin-1\u03b2 promotes the induction of retinal autoimmune disease","volume":"22","author":"Zhao","year":"2014","journal-title":"Int. Immunopharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","article-title":"Interleukin-1\u03b2-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet\u2019s disease: An open-label pilot study","volume":"71","author":"Gul","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/092739490500282","article-title":"Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: The Massachusetts eye & ear experience and review of previous studies","volume":"12","author":"Perez","year":"2004","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1167\/iovs.05-0444","article-title":"Multiplex bead immunoassay analysis of aqueous humor reveals distinct cytokine profiles in uveitis","volume":"46","author":"Curnow","year":"2005","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3109\/s10165-011-0497-5","article-title":"A case of Behcet\u2019s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab","volume":"22","author":"Hirano","year":"2012","journal-title":"Mod. Rheumatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1007\/s00417-013-2436-y","article-title":"Tocilizumab treatment for refractory uveitis-related cystoid macular edema","volume":"251","author":"Mesquida","year":"2013","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2147\/OPTH.S54929","article-title":"Acute anterior uveitis after discontinuation of tocilizumab in a patient with rheumatoid arthritis","volume":"8","author":"Sato","year":"2014","journal-title":"Clin. Ophthalmol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","article-title":"The use of interferon \u03b1 in Beh\u00e7et disease: Review of the literature","volume":"33","author":"Zierhut","year":"2004","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"12","DOI":"10.23937\/2378-346X\/1410012","article-title":"Effect of Interferon \u03b1-2a on peripheral blood CD4+ CD25+ T regulatory cells in patients with Beh\u00e7et uveitis: Preliminary study","volume":"2","author":"Koc","year":"2015","journal-title":"Int. J. Ophthalmol. Clin. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00417-008-1002-5","article-title":"Interferon-\u03b1-associated presumed ocular sarcoidosis","volume":"247","author":"Doycheva","year":"2009","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000336188","article-title":"Rituximab for noninfectious uveitis","volume":"51","author":"Miserocchi","year":"2012","journal-title":"Dev. Ophthalmol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3109\/s10165-008-0057-9","article-title":"Treatment of retinal vasculitis in Beh\u00e7et\u2019s disease with rituximab","volume":"18","author":"Sadreddini","year":"2008","journal-title":"Mod. Rheumatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/rheumatology\/ker107","article-title":"Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab)","volume":"50","author":"Heiligenhaus","year":"2011","journal-title":"Rheumatology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/bjophthalmol-2013-304686","article-title":"Treatment of diffuse subretinal fibrosis uveitis with rituximab","volume":"99","author":"Cornish","year":"2015","journal-title":"Br. J. Ophthalmol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/nm.2365","article-title":"A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy","volume":"17","author":"Wuest","year":"2011","journal-title":"Nat. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"18574","DOI":"10.3390\/ijms151018574","article-title":"Low-dose interleukin-2 therapy: A driver of an imbalance between immune tolerance and autoimmunity","volume":"15","author":"Kosmaczewska","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jcjo.2011.06.008","article-title":"Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease","volume":"46","author":"Wroblewski","year":"2011","journal-title":"Can. J. Ophthalmol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e90216","DOI":"10.1371\/journal.pone.0090216","article-title":"An anti-interleukin-2 receptor drug attenuates T-helper 1 lymphocytes-mediated inflammation in an acute model of endotoxin-induced uveitis","volume":"9","author":"Merida","year":"2014","journal-title":"PLoS ONE"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/rheumatology\/keg424","article-title":"Remission induction in Beh\u00e7et\u2019s disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H","volume":"42","author":"Lockwood","year":"2003","journal-title":"Rheumatology"},{"key":"ref_80","first-page":"1","article-title":"Management of uveitis-related choroidal neovascularization: From the pathogenesis to the therapy","volume":"450428","author":"Tortorella","year":"2014","journal-title":"J. Ophthalmol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1755-3768.2008.01208.x","article-title":"Therapeutic efficacy of intravitreal bevacizumab on posterior uveitis complicated by neovascularization","volume":"87","author":"Kurup","year":"2009","journal-title":"Acta Ophthalmol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1442-9071.2008.01727.x","article-title":"Intravitreal bevacizumab for choroidal neovascularisation secondary to punctate inner choroidopathy","volume":"36","author":"Vossmerbaeumer","year":"2008","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/09273940802650406","article-title":"Intravitreal bevacizumab for uveitic choroidal neovascularization","volume":"17","author":"Doctor","year":"2009","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.jcjo.2012.03.032","article-title":"Long-term ranibizumab treatment for choroidal neovascularization secondary to serpiginous choroiditis","volume":"47","author":"Balaskas","year":"2012","journal-title":"Can. J. Ophthalmol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s00417-014-2634-2","article-title":"Aflibercept for inflammatory choroidal neovascularization with persistent fluid on intravitreal ranibizumab therapy","volume":"252","year":"2014","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000162263","article-title":"Transient bevacizumab (avastin)-induced alterations in rat eyes","volume":"41","author":"Muriach","year":"2009","journal-title":"Ophthalmic Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/16\/8\/18778\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:50:32Z","timestamp":1760215832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/16\/8\/18778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,11]]},"references-count":86,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2015,8]]}},"alternative-id":["ijms160818778"],"URL":"https:\/\/doi.org\/10.3390\/ijms160818778","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725719555.793529295","asserted-by":"object"}]},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,11]]}}}